Hadarim Eating Disorders Unit, Shalvata Mental Health Centre, Hod Hasharon 4534708, Israel.
Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Nutrients. 2024 Feb 22;16(5):594. doi: 10.3390/nu16050594.
Eating disorders (EDs) are serious mental health conditions characterised by impaired eating behaviours and nutrition as well as disturbed body image, entailing considerable mortality and morbidity. Psychopharmacological medication is an important component in the treatment of EDs. In this review, we performed a historic analysis of pharmacotherapeutic research in EDs based on the scientific studies included in the recently published World Federation of Societies for Biological Psychiatry (WFSBP) guidelines for ED treatment. This analysis focuses on early approaches and trends in the methods of clinical pharmacological research in EDs, for example, the sample sizes of randomised controlled trials (RCTs). We found the development of psychopharmacological treatments for EDs followed advancements in psychiatric pharmacotherapy. However, the application of RCTs to the study of pharmacotherapy for EDs may be an impediment as limited participant numbers and inadequate research funding impede generalisability and statistical power. Moreover, current medication usage often deviates from guideline recommendations. In conclusion, the RCT model may not effectively capture the complexities of ED treatment, and funding limitations hinder research activity. Novel genetically/biologically based treatments are warranted. A more comprehensive understanding of EDs and individualised approaches should guide research and drug development for improved treatment outcomes.
进食障碍(EDs)是一种严重的心理健康状况,其特征为进食行为和营养受损以及身体形象障碍,导致相当高的死亡率和发病率。精神药理学药物治疗是 ED 治疗的重要组成部分。在这篇综述中,我们根据最近发表的世界生物精神病学学会联合会(WFSBP)ED 治疗指南中包含的科学研究,对 ED 中的药物治疗研究进行了历史性分析。该分析侧重于 ED 临床药理学研究方法的早期方法和趋势,例如随机对照试验(RCT)的样本量。我们发现 ED 精神药理学治疗的发展遵循精神药理学治疗的进展。然而,将 RCT 应用于 ED 药物治疗的研究可能会受到阻碍,因为参与者人数有限和研究资金不足会影响普遍性和统计效力。此外,目前的药物使用往往偏离指南建议。总之,RCT 模型可能无法有效地捕捉 ED 治疗的复杂性,资金限制阻碍了研究活动。有必要开发新的基于基因/生物学的治疗方法。更全面地了解 ED 并采用个体化方法应指导研究和药物开发,以改善治疗结果。